Unlock instant, AI-driven research and patent intelligence for your innovation.

Agents for reducing the activity of gdf15

A technology of X1X2X3X4X5X6X7X8X9, binding agent, applied in the direction of anti-animal/human immunoglobulin, animal/human protein, antibody mimic/scaffold, etc., can solve the problem of non-existence and difficult to reverse cachexia

Inactive Publication Date: 2018-06-08
GENAGON THERAPEUTICS
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Appetite stimulants are commonly used to compensate for loss of appetite in patients with advanced cancer, but to date there are currently no clinically available agents targeting the molecular mechanism of GDF15
Therefore, tumor-induced cachexia is difficult to reverse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agents for reducing the activity of gdf15
  • Agents for reducing the activity of gdf15
  • Agents for reducing the activity of gdf15

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-

[0301] Example 1 - Tandem Affinity Purification - Mass Spectrometry

[0302] We designed a protein-protein interaction capture assay using a panel of different proteins with the same affinity tag and included GDF15 to screen for interacting proteins. GDF15 was chosen for inclusion in the panel due to its important role in human pathology, including various cancers, and the lack of scientific literature on interacting proteins and receptors.

[0303] Design and construction of multiple bait proteins

[0304] Bioinformatics (SSPRO, RASMOL) analyzes were performed to rule out the presence of hydrophobic amino acids in the baits and to avoid disruption of known secondary structure elements. The bait insert was PCR amplified from plasmid DNA and inserted into a eukaryotic expression vector allowing gentamicin selection.

[0305] Cells were transfected with expression vectors, and overexpressed stable cell lines were generated in parallel against a panel of bait proteins, includ...

Embodiment 2

[0317] Example 2 - Purification of QRFPR-containing exosomes from conditioned media.

[0318] Exosome Isolation

[0319] Conditioned cell cultures were sequentially centrifuged at 3,000 x g for 5 min to pellet the cells and then at 10,000 x g for 10 min to further remove cells and cell debris. The supernatant was then filtered through a 0.45 μm filter and finally pelleted at 100,000 x g for 2 h at 4°C. The pelleted exosomes were resuspended in PBS and protease inhibitors (completemini, Roche) added. Samples were then prepared for further analysis as described elsewhere.

[0320] Exosome Identification by Electron Microscopy

[0321] Clumped exosomes were precipitated on 20-mesh polymethylvinyl acetate / carbon-coated copper grids (polysciences, Inc.), and then detected by transmission electron microscopy at 80 kV in a Technai G2 (FEI). (TEM) for analysis ( figure 1 A).

[0322] Western blot identification of QRFPR-positive exosomes

[0323] The material from the ultrac...

Embodiment 3

[0324] Example 3 - Detection of GDF15-QRFPR on the cell surface

[0325] To investigate the presence of the complex between GDF15 and QRFPR on the cell surface, we analyzed MCF-7 treated with sulindac sulfide (an NSAID to increase the amount of low endogenous GDF15) using in situ PLA cells to examine the interaction between GDF15 and QRFPR. We compared siRNA against QRFPR ( figure 2 B) or control siRNA wrapped with sequence ( figure 2 A) Levels of proximity events between GDF15 and QRFPR in treated MCF-7 cells. We detected reduced GDF15-QRFPR levels in QRFPR siRNA-treated cells, confirming the specificity of the antibody and the presence of the receptor in this cell line. Cells were serum starved prior to GDF15 treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to agents for reducing the activity of GDF15 and in particular the use of such agents to treat or prevent conditions associated with elevated or unwanted levels of GDF15.The invention is based on the discovery that GDF15 binds to the receptors CLPTM1 and QRFPR and provides agents for such use in the form of binding agents capable of binding to the receptors and inhibiting the interaction between GDF15 and the receptor. Further agents include polypeptides derived from the receptors which are capable of binding to GDF15 and inhibiting its interaction with the receptors. Also provided are diagnostic methods based on detecting the interaction or an effect thereof, and cytotoxic immune cells modified to have a reduced level and / or activity of CLPTM1.

Description

technical field [0001] The present invention relates to formulations for reducing the activity of GDF15, including therapeutic agents that can be used in a subject to combat (ie treat or prevent) symptoms associated with elevated, excessive or undesired GDF15 levels and / or activity in the body . The present invention is based on the discovery of two different receptors for GDF15 in the body, and thus on this identification of novel GDF-15 receptors, the present invention more particularly provides fragments of said receptors directed against GDF15 as well as GDF15 receptor-binding Antibodies or other affinity binding reagents for preventing binding of GDF15 to its receptor and / or otherwise inhibiting the effect of GDF15 at one or both of the two receptors (ie the effect of binding of GDF15). Background technique [0002] Growth and differentiation factor 15 (GDF15), also known as macrophage inhibitory factor (MIC1), is a member of the TGF-β superfamily and has a relatively ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K14/705
CPCA61P35/04C07K14/705C07K16/22C07K16/2863C07K2317/34C07K2317/76C07K2317/24C07K2319/30
Inventor O·A·布洛克泽尔J·E·S·弗雷德里克松
Owner GENAGON THERAPEUTICS